Continuous Intraocular Pressure (IOP) Monitor

About InjectSense

InjectSense is pioneering a new category of digital health through its ultra-miniaturized, implantable sensor platform designed for continuous, long-term physiological monitoring. The company's core innovation lies in merging semiconductor manufacturing techniques—specifically wafer-scale packaging for scalability—with medical device development to create autonomous, rechargeable, and wireless sensors. Having completed its first human implantation in 2024, InjectSense is initially targeting the glaucoma market with a sensor smaller than a grain of rice, aiming to shift disease management from episodic clinic measurements to continuous data streams. The company's supply-chain-ready design and focus on actionable, AI-ready data position it to potentially transform therapy management across multiple chronic conditions.

Therapeutic Areas